GILD
NasdaqGILEAD SCIENCES, INC.
Health Care, Biotechnology
$133.21
close 7 Aug 2026
+10.58%
52-week change
$165.31B
market cap
$108.46
$157.29
52-week range
| Line item | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||||||||
| Revenue | $30.46B | $29.44B | $28.75B | $27.12B | $27.28B | $27.31B | $24.69B | $22.45B | $22.13B | $26.11B | $30.39B | $32.64B | $24.89B | $11.20B | $9.70B | $8.39B | $7.95B | $7.01B | $5.34B | $4.23B |
| Cost of revenue | $6.22B | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B | $4.57B | $4.68B | $4.85B | $4.37B | $4.26B | $4.01B | $3.79B | $2.86B | $2.47B | $2.12B | $1.87B | $1.60B | $1.13B | $768.77M |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| R&D | $6.07B | $5.80B | $5.91B | $5.72B | $4.98B | $4.60B | $4.93B | $4.06B | $3.92B | $3.73B | $5.10B | $3.01B | $2.85B | $2.12B | $1.76B | $1.23B | $1.07B | $939.92M | $721.77M | $591.03M |
| SG&A | $6.52B | $5.77B | $6.09B | $6.09B | $5.67B | $5.25B | $5.15B | $4.38B | $4.06B | $3.88B | $3.40B | $3.43B | $2.98B | $1.70B | $1.46B | $1.24B | $1.04B | $946.69M | $797.34M | $705.74M |
| Operating income | -$2.50B | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B | $4.29B | $8.20B | $14.12B | $17.63B | $22.19B | $15.27B | $4.52B | $4.01B | $3.79B | $3.96B | $3.53B | $2.68B | $2.16B |
| Interest expense | $997.00M | $1.02B | $977.00M | $944.00M | $935.00M | $1.00B | $984.00M | $995.00M | $1.08B | $1.12B | $964.00M | $688.00M | $412.00M | $307.00M | $361.00M | $205.42M | $108.96M | $69.66M | $65.24M | $63.18M |
| Tax expense | $1.29B | $1.29B | $211.00M | $1.25B | $1.25B | $2.08B | $1.58B | -$204.00M | $2.34B | $8.89B | $3.61B | $3.55B | $2.80B | $1.15B | $1.04B | $861.95M | $1.02B | $876.36M | $702.36M | $635.36M |
| Net income | -$3.24B | $8.51B | $480.00M | $5.67B | $4.59B | $6.23B | $123.00M | $5.39B | $5.46B | $4.63B | $13.50B | $18.11B | $12.10B | $3.08B | $2.59B | $2.80B | $2.90B | $2.64B | $1.98B | $1.58B |
| Diluted EPS | -$2.66 | $6.78 | $0.3800 | $4.50 | $3.64 | $4.93 | $0.1000 | $4.22 | $4.17 | $3.51 | $9.94 | $11.91 | $7.35 | $1.81 | $1.64 | $1.77 | $1.66 | $2.82 | $2.06 | $1.64 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -8.20% | 34.04% | 5.78% | 28.05% | 26.87% | 36.32% | 16.49% | 19.10% | 37.06% | 54.10% | 58.02% | 68.00% | 61.33% | 40.39% | 41.33% | 45.20% | 49.84% | 50.34% | 50.20% | 51.17% |
| Net margin | -10.64% | 28.90% | 1.67% | 20.89% | 16.83% | 22.80% | 0.50% | 23.99% | 24.65% | 17.73% | 44.43% | 55.48% | 48.62% | 27.45% | 26.72% | 33.43% | 36.50% | 37.59% | 37.09% | 37.47% |
filed 6 Aug 2026